Hoth Therapeutics Inc (HOTH) concluded trading on Thursday at a closing price of $0.76, with 8.53 million shares of worth about $6.49 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -17.08% during that period and on December 26, 2024 the price saw a loss of about -3.43%. Currently the company’s common shares owned by public are about 6.90M shares, out of which, 6.84M shares are available for trading.
Stock saw a price change of -4.39% in past 5 days and over the past one month there was a price change of -7.65%. Year-to-date (YTD), HOTH shares are showing a performance of -47.22% which decreased to -43.70% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.58 but also hit the highest price of $1.73 during that period. The average intraday trading volume for Hoth Therapeutics Inc shares is 952.91K. The stock is currently trading -7.62% below its 20-day simple moving average (SMA20), while that difference is down -10.55% for SMA50 and it goes to -21.73% lower than SMA200.
Hoth Therapeutics Inc (NASDAQ: HOTH) currently have 6.90M outstanding shares and institutions hold larger chunk of about 5.31% of that.
The stock has a current market capitalization of $5.24M and its 3Y-monthly beta is at 0.74. It has posted earnings per share of -$1.40 in the same period. It has Quick Ratio of 10.16 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HOTH, volatility over the week remained 10.24% while standing at 6.61% over the month.
Stock’s fiscal year EPS is expected to rise by 44.78% while it is estimated to increase by 50.39% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by The Benchmark Company on October 15, 2019 offering a Speculative buy rating for the stock and assigned a target price of $10 to it.
